Search the Newsreel

T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5%

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 17.4% of Immunome, Inc. common stock, totaling 19,676,883 shares, according to a recent SEC filing. The firm holds sole voting power over 19,656,814 shares and sole dispositive power over all 19,676,883 shares. …

HC Wainwright Issues Negative Forecast for Immunome Earnings

Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A

Sirenia Capital Management LP and Alex Silverstein have reported a 4.3% beneficial ownership stake in Immunome Inc. (IMNM) through an amended Schedule 13G filing. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the 113,250,394 shares outstanding as of May 7, 2026. …

Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade

Immunome (NASDAQ:IMNM) shares hit a new 52-week high of $28.04 after Truist Financial raised its price target to $38 from $37, maintaining a "Buy" rating. Despite a larger-than-expected quarterly loss and significant insider selling, analyst sentiment remains largely positive, with a consensus price target …

Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027

Immunome is advancing varegacestat for desmoid tumors after its Phase 3 RINGSIDE study showed an 84% reduction in disease progression or death risk. The FDA has accepted the New Drug Application with a target action date of April 28, 2027, and the company plans …

Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares

Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 11,048 shares of the company's stock for over $301,000, reducing his holdings by 10.7%. This sale is part of a series of transactions under a pre-arranged trading plan, totaling about $2.6 million from August 10-12. Despite the sales …

Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com

Immunome director Isaac Barchas sold over $2.19 million worth of company shares in August 2026 through pre-arranged Rule 10b5-1 trading plans. These sales included shares held indirectly by AMBHMC II LLC and directly by Barchas, following which he directly holds 92,211 shares. The sales …

Immunome, Inc. Stock 12‑Month Price Target Raised to $36.31, Implies 38% Upside

Immunome, Inc.'s average 12-month price target has been increased to $36.31 by 13 analysts, up from $35.77, with individual forecasts ranging from $30 to $40 per share. This new target suggests a potential upside of approximately 38% from its August 11 closing price. The …

Immunome (NASDAQ:IMNM) Stock Price Expected to Rise, Truist Financial Analyst Says

Immunome stock hits 52-week high at 27.68 USD

Immunome Inc. (IMNM) stock has reached a new 52-week high of $27.68, reflecting significant investor confidence with a 1-year change of 175.42%. Despite InvestingPro analysis suggesting the shares may be overvalued, analysts have revised earnings upwards, with price targets ranging from $30 to $40. …

Immunome Inc. SEC Filing (Aug 12, 2026)

This article reports on an Immunome Inc. SEC Filing (Form 144) submitted on August 12, 2026, which details a proposed sale of 11,048 shares of common stock with an aggregate market value of $301,058.00. The filing, accepted by the SEC EDGAR at 11:40 AM …

Immunome (NASDAQ:IMNM) Shares Gap Down on Disappointing Earnings

Immunome Inc. Q2 2026: Revenue $0 Net loss $73.1M, EPS $(0.65) — 10-Q Summary

Immunome Inc. reported Q2 2026 financial results, showing zero revenue and a net loss of $73.1 million, or $(0.65) per diluted share. This is a decline compared to the prior year's Q2 2025, which had $4 million in revenue and a net loss of …

Immunome Q2 Results: EPS Misses Estimate, Losses Widen 30% YoY

Immunome Inc. reported a Q2 2026 net loss of $73.1 million, significantly wider than the previous year, primarily due to increased R&D and administrative expenses, and missed EPS estimates. Despite financial challenges, the company secured FDA acceptance for its varegacestat NDA with a PDUFA …

Immunome (IMNM) widens losses as it funds oncology pipeline with $520M cash

Immunome (NASDAQ:IMNM) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Immunome (NASDAQ:IMNM) announced its quarterly earnings, reporting a loss of $0.65 per share, which missed the consensus estimate by $0.14. Despite the earnings miss, the stock rose by $0.56 to $26.25, and analysts largely maintain a "Moderate Buy" rating with a $34.18 average price …

Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 15,248 Shares

Immunome (NASDAQ:IMNM) Director Isaac Barchas sold 15,248 shares of the company's stock on August 7th for over $397,000, reducing his direct holdings by 17.39%. This sale was part of a pre-arranged Rule 10b5-1 plan, and he has sold more than 320,000 shares since late …

Price to sales forward of Immunome, Inc. – NASDAQ:IMNM

This article displays the "Price to sales forward" metric for Immunome, Inc. (NASDAQ: IMNM) on TradingView. It presents financial data for the company, indicating the value, change, and percentage change for this specific financial ratio. The content is primarily a data point rather than …

Immunome CBO Kinney Horn sells $2.27m in company stock

Immunome's Chief Business Officer, Kinney Horn, sold 90,616 shares of company stock for $2.27 million after exercising employee stock options. This transaction occurred when the stock was near its 52-week high and followed a 162% gain over the past year. InvestingPro analysis suggests the …

Immunome (NASDAQ:IMNM) Insider Sells $2,273,555.44 in Stock

Immunome (NASDAQ:IMNM) insider Kinney Horn sold 90,616 shares of the company's stock for approximately $2.27 million on August 4th, reducing their direct ownership by 64.27%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. The clinical-stage biotechnology company, which focuses on antibody-based …

IMNM (IMNM) investor ABHMC II LLC plans sale of 108,504 common shares

ABHMC II LLC, an investor in Immunome Inc. (IMNM), plans to sell 108,504 common shares via Merrill Lynch on or after August 6, 2026. These shares, valued at approximately $2.77 million, were acquired through a private placement on October 3, 2023. The filing also …

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. announced that its Compensation Committee granted inducement awards of non-statutory stock options to nine new employees on August 3, 2026. These options allow them to purchase an aggregate of 176,500 shares of common stock at an exercise price of $23.01 per share. …

Edgestream Partners L.P. Makes New $1.31 Million Investment in Immunome, Inc. $IMNM

Edgestream Partners L.P. has made a new $1.31 million investment in Immunome, Inc. (NASDAQ:IMNM), acquiring 59,888 shares. This investment highlights continued institutional interest, with other hedge funds also adjusting their positions, bringing total institutional ownership to 44.58%. Despite analyst recommendations for a "Moderate Buy" …

Insider at IMNM (NASDAQ: IMNM) plans sale of 90,616 shares

Alfred K. Horn, an insider at Immunome Inc. (NASDAQ: IMNM), has filed a Form 144 notice to sell up to 90,616 shares of common stock on August 4, 2026, through Fidelity Brokerage Services LLC. This planned sale is in connection with a stock option …

Price to earnings forward of Immunome, Inc. – NASDAQ:IMNM

This article provides a brief overview of Immunome, Inc. (NASDAQ: IMNM) financials, specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a section of a larger financial data page on TradingView, indicating that the detailed financial figures for …

Immunome Inc (IMNM) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of Immunome Inc (IMNM), noting its robust financial status with a score of 7.15 out of 10, ranking 137th in the Biotechnology & Medical Research industry. Despite this, the company exhibits low operating efficiency, with recent quarterly revenue …

Immunome Stock Price Forecast. Should You Buy IMNM?

Immunome Inc (IMNM) Valuation: PE, PB & Fair Value Analysis

Immunome Inc (IMNM) currently has a valuation score of 8.36, placing it 136th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -9.69, which is significantly below its recent high and slightly above its recent low. Key …

(IMNM) Volatility Zones as Tactical Triggers

This article analyzes Immunome Inc. (NASDAQ: IMNM), identifying a mid-channel oscillation pattern and a strong risk-reward short setup. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report also notes a …

Immunome (IMNM) Expected to Post Earnings on Wednesday

Immunome Inc (IMNM) Institutional Confidence

Immunome Inc (IMNM) has an institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry, with institutional ownership at 102.66%, up 21.95% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.06% of shares outstanding. Key institutional investors include Fidelity …

Immunome Inc. (IMNM) Q1 2026 Earnings: EPS Beat Driven by Lower Operating Expenses - Revenue Guidance Update

Immunome Inc. (IMNM) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Immunome Inc. (IMNM) stock on NASDAQ, showing a current price of $22.67 with a gain of 2.07%. It indicates that information on analyst ratings and earnings is not currently available for Immunome Inc. The broader content …